Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708)

IF 2.7 3区医学 Q3 ONCOLOGY

Clinical and Translational Radiation Oncology Pub Date : 2024-10-06 DOI:10.1016/j.ctro.2024.100874

K. Zwart , M.N.G.J.A. Braat , F.H. van der Baan , A.M. May , J.M.L. Roodhart , D. Al-Toma , J.M.M.B. Otten , M. Los , T. Oostergo , R.J.A. Fijneman , J.M. van Dodewaard-de Jong , C.J.A Punt , G. Meijer , J.J.W. Lagendijk , M. Koopman , M. Intven , G.M. Bol

引用次数: 0

Abstract

Colorectal cancer patients with ≤10 unresectable metastases were treated with single-fraction sub-ablative radiotherapy in addition to standard of care systemic therapy in a single-arm, open-label, multicenter, pilot study (SIRIUS) to assess feasibility and safety. Results indicate that radiotherapy combined with systemic therapy is feasible and safe in this population.

查看原文本刊更多论文

对转移灶≤10个的结直肠癌患者进行单次分割亚烧蚀放疗联合全身治疗的可行性和安全性：一项多中心试点研究 (NCT05375708)

在一项单臂、开放标签、多中心、试验性研究（SIRIUS）中，患有≤10个不可切除转移灶的结直肠癌患者在接受标准全身治疗的同时，还接受了单次分次烧蚀放疗，以评估其可行性和安全性。结果表明，在这一人群中，放疗结合全身治疗是可行且安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊